AlphAIalphai — Financial news for AI agents
Stock TitanAPR 293 min read$VTVT

vTv Therapeutics (NASDAQ: VTVT) details 2026 virtual annual meeting, board and pay

vTv Therapeutics is holding its 2026 annual virtual-only meeting on June 10, 2026, where stockholders will vote on electing seven directors and ratifying Ernst & Young LLP as the independent auditor. The proxy statement details the company's governance structure, board composition, director compensation, and executive compensation for 2025, including CEO Paul Sekhri's $6.64 million total compensation and CFO Michael Tung's $2.44 million. Key investors, including MacAndrews & Forbes and several institutional investors, hold significant stakes and have board nomination rights.

Original reporting
Stock Titan
Published Apr 29, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 29, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
vTv Therapeutics (NASDAQ: VTVT) details 2026 virtual annual meeting, board and pay — source image
Source · Stock Titan
Decision brief

The 30-second read

$VTVTNeutralMed
01

Why it matters

Such events can temporarily influence stock price and investor sentiment, especially if significant changes or controversies arise.

02

Market read

The event is primarily relevant to investors and stakeholders in vTv Therapeutics, with limited broader market impact.

03

What to watch

Potential for broader industry or market movements to overshadow company-specific events.

Timing: High, as the meeting is scheduled for June 10, 2026.

Background

vTv Therapeutics is preparing for its 2026 virtual annual shareholder meeting, where key governance and compensation issues will be addressed.

Company-level read

Ticker impact

$VTVTNeutralMedium confidence
Context

High relevance due to upcoming shareholder meeting and executive compensation disclosures.

Expected impact

Moderate increase in volatility around June 10, 2026, with potential short-term price stabilization.

Evidence & confidence

While governance updates can impact sentiment, the overall effect is limited without material changes or news.

Market effects

Sector

Potential influence on life sciences sector sentiment due to governance transparency.

Regional

Limited regional impact; primarily relevant to US investors.

Global

Minimal global market effect unless material corporate changes occur.

Counterpoint

What could challenge this read

The meeting's disclosures are unlikely to significantly impact stock price unless unexpected material news emerges.

Key entities

  • Company
    vTv Therapeutics

    A life sciences company focused on developing therapies for chronic diseases.

  • CEO
    Paul Sekhri

    Chief Executive Officer with a reported compensation of $6.64 million in 2025.

  • Auditor
    Ernst & Young LLP

    Independent auditing firm ratified as auditor for 2026.

Read at source← All news

Related articles

AUG 6
$VTVTMed

vTv Therapeutics Inc. (VTVT): Results of Operations and Financial Condition

vTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid

SEC EDGAR 8-K5 min
SEP 5
$AVEXMed

AVEX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages AVEX Investors with Losses to Contact the Firm

AEVEX Corp. (NYSE: AVEX) faces a securities fraud class action lawsuit over alleged misstatements regarding a secondary public offering. The lawsuit covers investors who bought shares between April 17, 2026, and June 4, 2026. The stock dropped 16% on June 2, 2026, and 7% on June 5, 2026, following disclosures about the offering. Investors have until October 20, 2026, to seek lead plaintiff status.

prnewswire.com2 min
SEP 5
$BAHighAI 9/10

US okays $5.75 billion munitions, engines sale to Saudi Arabia

The US State Department approved a $5 billion sale of Joint Direct Attack Munitions-Extend Range and a $750 million sale of AGT-1500 engines to Saudi Arabia. Boeing and Honeywell are the principal contractors, respectively. The sales aim to enhance Saudi Arabia's defense capabilities and regional interoperability, according to the State Department.

middleeasteye.net2 min
SEP 4
$AVAVLowAI 8/10

Jim Cramer Highlights AeroVironment’s (AVAV) Steep Competition

Jim Cramer advised against investing in AeroVironment (AVAV) despite a 40% stock drop, citing intense competition in the defense sector. The company reported record revenue of $1.98B for FY2026, up 141% YoY, driven by strong defense demand and a $464.8M U.S. Army contract. However, competition from firms like RTX and Lockheed Martin may pressure margins. Hedge fund interest grew, but short interest remains high at 9.55%.

insidermonkey.com1 min